1 / 34

Calcium Channel Blocking Drugs

Calcium Channel Blocking Drugs. Outline. Pharmacokinetics Adverse effects Contraindications Summary. Introduction CCB binding sites Heterogeneity of action Cardiac & hemodynamic differentiation. Chemical Type. Chemical Names. Brand Names. Phenylalkylamines. verapamil.

meredith-moss
Télécharger la présentation

Calcium Channel Blocking Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Calcium Channel Blocking Drugs

  2. Outline • Pharmacokinetics • Adverse effects • Contraindications • Summary • Introduction • CCB binding sites • Heterogeneity of action • Cardiac & hemodynamic differentiation

  3. Chemical Type Chemical Names Brand Names Phenylalkylamines verapamil Calan, Calna SR, Isoptin SR, Verelan Benzothiazepines diltiazem Cardizem CD, Dilacor XR 1,4-Dihydropyridines Nifedipine nicardipine isradipine felodipine amlodipine Adalat CC, Procardia XL Cardene DynaCirc Plendil Norvasc Three Classes of CCBs

  4. Three Classes of CCBs H3C CH3 CH3 H3C 0 0 CH3 CH CH2 CH3 0 0 C CH2 N CH2 CH2 CH2 H3C N C Verapamil NO2 CH3 S N CH2 N CH2 0 0 CH3 C 0 H3C 0 C CH3 C CH3 0 0 H3C CH3 0 N H CH3 Diltiazem Nifedipine

  5. Widespread use of CCBs • Angina pectoris • Hypertension • Treatment of supraventricular arrhythmias - Atrial Flutter - Atrial Fibrillation • - Paroxysmal SVT

  6. Outline • Pharmacokinetics • Adverse effects • Contraindications • Summary • Introduction • CCB binding sites • Heterogeneity of action • Cardiac & hemodynamic differentiation

  7. I II III IV Out In 6 IV III 5 5 IV III 6 II I The 1C subunit of the L-type Ca2+ channel is the pore-forming subunit

  8. a2 a1C NH3+ COO- I II III IV NH3+ COO- d COO- NH3+ b NH3+ COO- The expression and function of the 1C subunit is modulated by other smaller subunits L-Type Ca2+ Channel

  9. 1,4- Dihydropyridines (nifedipine) - + - + Ca2+ pore - - Phenylalkylamines (verapamil) Benzothiazepines (diltiazem) - The Three Classes of CCBs Bind to Different Sites

  10. CCBs – Mechanisms of Action • Increase the time that Ca2+ channels are closed • Relaxation of the arterial smooth muscle but not much effect on venous smooth muscle • Significant reduction in afterload but not preload

  11. The different binding sites of CCBs result in differing pharmacological effects Use-dependent binding (targets cardiac cells) out +20  2 mV 1 Cell membrane 1  -80 in  Diltiazem Verapamil Voltage-dependent binding (targets smooth muscle) +20 out  -30 2 Cell membrane 1 -80 1  mV in  Nifedipine

  12. Outline • Pharmacokinetics • Adverse effects • Contraindications • Summary • Introduction • CCB binding sites • Heterogeneity of action • Cardiac & hemodynamic differentiation

  13. Why Do CCBs Act Selectively on Cardiac and Vascular Muscle?

  14. N-type and P-type Ca2+ channels mediate neurotransmitter release in neurons Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ postsynaptic cell

  15. Myofibril Plasma membrane Transverse tubule Terminal cisterna of SR Triad SR T Tubules of SR Skeletal muscle relies on intracellular Ca2+ for contraction

  16. Ca2+ Ca2+ L-Type L-Type Ca2+ Ca2+ Ca2+ Contractile Cells (atria, ventricle) Slow Response Cells (SA node, AV node) Cardiac cells rely on L-type Ca2+ channels for contraction and for the upstroke of the AP in slow response cells

  17. Ca2+ L-Type (graded, Ca2+ dependent contraction) Vascular smooth muscle relies on Ca2+ influx through L-type Ca2+ channels for contraction

  18. CCBs Act Selectively on Cardiovascular Tissues • Neurons rely on N-and P-type Ca2+ channels • Skeletal muscle relies primarily on [Ca]i • Cardiac muscle requires Ca2+ influx through L-type Ca2+ channels - contraction (fast response cells) - upstroke of AP (slow response cells) • Vascular smooth muscle requires Ca2+ influx through L-type Ca2+ channels for contraction

  19. Outline • Pharmacokinetics • Adverse effects • Contraindications • Summary • Introduction • CCB binding sites • Heterogeneity of action • Cardiac & hemodynamic differentiation

  20. The different binding sites of CCBs result in differing pharmacological effects Use-dependent binding (targets cardiac cells) out +20  2 mV 1 Cell membrane 1  -80 in  Diltiazem Verapamil Voltage-dependent binding (targets smooth muscle) +20 out  -30 2 Cell membrane 1 -80 1  mV in  Nifedipine

  21. Peripheral vasodilation Differential effects of different CCBs on CV cells Dihydropyridines: Selective vasodilators Non -dihydropyridines: equipotent for cardiac tissue and vasculature Heart rate moderating Peripheral and coronary vasodilation SN AV Potential reflex increase in HR, myocardial contractility and O2 demand Coronary VD SN AV Reduced inotropism

  22. Effect Verapamil Diltiazem Nifedipine Peripheral vasodilatation    Coronary vasodilatation    Preload 0 0 0/ Afterload    Contractility  0/ /* Heart rate 0/  /0 AV conduction   0 Hemodynamic Effects of CCBs

  23. Outline • Pharmacokinetics • Adverse effects • Contraindications • Summary • Introduction • CCB binding sites • Heterogeneity of action • Cardiac & hemodynamic differentiation

  24. Agent Oral Absorption (%) Protein Bound (%) Elimination Half-Life (h) Bioavail- Ability (%) Verapamil >90 10-35 83-92 2.8-6.3* Diltiazem >90 41-67 77-80 3.5-7 Nifedipine >90 45-86 92-98 1.9-5.8 Nicardipine -100 35 >95 2-4 Isradipine >90 15-24 >95 8-9 Felodipine -100 20 >99 11-16 Amlodipine >90 64-90 97-99 30-50 CCBs: Pharmacokinetics

  25. Outline • Pharmacokinetics • Adverse effects • Contraindications • Summary • Introduction • CCB binding sites • Heterogeneity of action • Cardiac & hemodynamic differentiation

  26. Diltiazem Verapamil Dihydropyridines Overall 0-3% 10-14% 9-39% Hypotension ++ ++ +++ Headaches 0 + +++ Peripheral Edema ++ ++ +++ Constipation 0 ++ 0 CHF (Worsen) 0 + 0 AV block + ++ 0 Caution w/beta blockers + ++ 0 Comparative Adverse Effects

  27. CCBs - Monitoring • heart rate • blood pressure • anginal symptoms • signs of CHF • adverse effects

  28. Outline • Pharmacokinetics • Adverse effects • Contraindications • Summary • Introduction • CCB binding sites • Heterogeneity of action • Cardiac & hemodynamic differentiation

  29. Contraindication Verapamil Nifedipine Diltiazem Hypotension + ++ + Sinus bradycardia + 0 + AV conduction defects ++ 0 ++ Severe cardiac failure ++ + + Contradications for CCBs

  30. Outline • Pharmacokinetics • Adverse effects • Contraindications • Summary • Introduction • CCB binding sites • Heterogeneity of action • Cardiac & hemodynamic differentiation

  31. Which CCB is most likely to cause hypotension and reflex tachycardia? • Diltiazem • Nifedipine • Verapamil

  32. Contraindications for CCBs include (choose all appropriate): • Supraventricular tachycardias • Hypotension • AV heart block • Hypertension • Congestive heart failure

  33. CCBs may improve cardiac function by: • Reducing cardiac afterload • Increasing O2 supply • Decreasing cardiac preload • Normalizing heart rate in patients with • supraventricular tachycardias

  34. Thank you!

More Related